NASDAQ$TNYA

Tenaya Therapeutics Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Reported financial results for the second quarter of 2021 and provided business updates.

Tenaya Therapeutics reported its Q2 2021 financial results, highlighting a successful IPO that raised $207 million and progress in advancing their gene therapy and precision medicine platforms.

  • TN-201 received Orphan Drug Designation from the FDA.
  • Expanded leadership team with key appointments.
  • Completed Initial Public Offering, raising $207 million in gross proceeds.
  • Advanced TN-201 and TYA-11631 programs towards INDs in 2022.

Headline financials

EPS (adj)

-$13.26

Previous: -$0.32-4031.0%
Net Income

-$15.2M

Previous: -$8.73M-74.2%
Operating Income

-$15.2M

Previous: -$8.87M-71.7%
Cash & Equivalents

$112M

No prior period

Revenue & EPS history

Tenaya Therapeutics · Revenue · Quarterly

$225K

Q1 2026
Beat estimate in 0 of 2 quarters(0%)
ActualEstimate

Forward guidance

Tenaya expects its current cash and cash equivalents, including the net proceeds from the IPO, will be sufficient to fund its current operating plan at least into the 2nd half of 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports

Historical avg

+2.8%

Avg return

Earnings day

+2.1%

Avg return

5 days after

-5.6%

Avg return

30 days after

50%

9 / 18 earnings

Positive

+39.8%

Q3 2022

Best reaction

-18.7%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.8%+30.3%-4.2%
Q4 2025-1.3%-0.2%-19.7%
Q3 2025-1.4%-7.0%-4.9%
Q1 2025+7.8%-3.3%+38.2%
Q4 2024-6.5%-12.7%-38.4%
Q3 2024+17.4%+20.7%+68.1%
Q1 2024-0.7%+8.9%-12.6%
Q4 2023-8.9%-5.1%-13.6%
Q3 2023-7.8%-10.2%-2.9%
Q2 2023+7.3%+0.0%-24.6%
Q1 2023+12.1%+7.2%+9.0%
Q4 2022-18.7%-20.6%-25.9%
Q3 2022+39.8%+53.4%+11.0%
Q2 2022+1.5%+6.5%-11.3%
Q1 2022-5.7%-6.7%-29.9%
Q4 2021+6.0%+3.2%-5.0%
Q3 2021+7.7%-13.5%-28.1%
Q2 2021-2.8%-12.6%-6.5%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro